Dendreon Defends Provenge’s Stake Against Arrival Of Abiraterone

Dendreon Corp. is defending Provenge's position as the “foundation of care” for castration-resistant prostate cancer, following the recent approval of Johnson & Johnson’s Zytiga, and looking ahead to other novel drugs coming down the pike.